{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:38:10Z","timestamp":1790501890801,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Beijing Municipal Science and Technology Commission"},{"DOI":"10.13039\/501100001809","name":"China National Nature Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Center for Life Sciences at Tsinghua and Peking Universities"},{"name":"China Recruitment Program of Global Experts"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejpb.2017.12.016","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T18:16:44Z","timestamp":1514917004000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Oral bioavailability enhancement of \u03b2-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion"],"prefix":"10.1016","volume":"124","author":[{"given":"Chengyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipshu","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2017.12.016_b0005","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","article-title":"Improving oral bioavailability of sorafenib by optimizing the \u201cSpring\u201d and \u201cParachute\u201d based on molecular interaction mechanisms","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1568009023333854","article-title":"Cancer therapy with beta-lapachone","volume":"2","author":"Pardee","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejpb.2017.12.016_b0025","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1023\/A:1026143519395","article-title":"Enhancement of solubility and bioavailability of \u03b2-lapachone using cyclodextrin inclusion complexes","volume":"20","author":"Nasongkla","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.12.016_b0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2007.04.014","article-title":"\u03b2-Lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells","volume":"122","author":"Blanco","year":"2007","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2017.12.016_b0035","first-page":"1","article-title":"Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of \u03b2-lapachone","author":"Ma","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejpb.2017.12.016_b0040","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1200\/jco.2007.25.18_suppl.16509","article-title":"A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck","volume":"25","author":"Kawecki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2017.12.016_b0045","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jps.2600571102","article-title":"Particle size of drugs and its relationship to absorption and activity","volume":"57","author":"Fincher","year":"1968","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0050","series-title":"Pharmaceutics: The Science of Dosage Form Design","author":"Aulton","year":"2001"},{"key":"10.1016\/j.ejpb.2017.12.016_b0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.40","article-title":"Solid dispersions: revival with greater possibilities and applications in oral drug delivery","volume":"20","author":"Sethia","year":"2003","journal-title":"Crit. Rev. Ther. Drug Carrier"},{"key":"10.1016\/j.ejpb.2017.12.016_b0060","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2017.12.016_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","article-title":"Improving drug solubility for oral delivery using solid dispersions","volume":"50","author":"Leuner","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"Mooter","year":"2011","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2017.12.016_b0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.powtec.2013.06.039","article-title":"Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions","volume":"247","author":"Shi","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2017.12.016_b0080","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3109\/03639045.2012.725731","article-title":"To evaluate the change in release from solid dispersion using sodium lauryl sulfate and model drug sulfathiazole","volume":"39","author":"Dave","year":"2013","journal-title":"Drug Develop. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejpb.2006.12.016","article-title":"Performance comparison of a co-crystal of carbamazepine with marketed product","volume":"67","author":"Hickey","year":"2007","journal-title":"Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"10.1016\/j.ejpb.2017.12.016_b0090","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s11095-008-9676-2","article-title":"Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds","volume":"25","author":"Shiraki","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.12.016_b0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s11095-007-9275-7","article-title":"Mechanistic investigation of Pluronic based nano-crystalline drug-polymer solid dispersions","volume":"24","author":"Qian","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.12.016_b0100","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/mp500661v","article-title":"Crystallization of bifonazole and acetaminophen within the matrix of semicrystalline, PEO\u2212PPO\u2212PEO triblock copolymers","volume":"12","author":"Chen","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0105","doi-asserted-by":"crossref","DOI":"10.1021\/acs.cgd.6b00879","article-title":"Dissolution characteristics of fast-crystallizing \u03b2-lapachone within different semicrystalline microstructures of polyethylene glycol or poly(ethylene oxide)\u2013poly(propylene oxide)\u2013poly(ethylene oxide) triblock copolymer","author":"Chen","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2017.12.016_b0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Cryst."},{"key":"10.1016\/j.ejpb.2017.12.016_b0115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/mp500660m","article-title":"Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions","volume":"12","author":"Chen","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0120","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejps.2013.01.004","article-title":"The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus\u00ae-based solid dispersions","volume":"48","author":"Hughey","year":"2013","journal-title":"Eur. J. Pharm Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2015.03.053","article-title":"Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations","volume":"486","author":"D\u00e9muth","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0130","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-016-1969-2","article-title":"Initial drug dissolution from amorphous solid dispersions controlled by polymer dissolution and drug-polymer interaction","author":"Chen","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.12.016_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0001-8686(75)85001-9","article-title":"Ostwald ripening of precipitates","volume":"5","author":"Kahlweit","year":"1975","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0140","doi-asserted-by":"crossref","first-page":"7691","DOI":"10.1103\/PhysRevE.58.7691","article-title":"Diffusion-driven phase separation of deeply quenched mixtures","volume":"58","author":"Vladimirova","year":"1998","journal-title":"Phys. Rev. E"},{"key":"10.1016\/j.ejpb.2017.12.016_b0145","series-title":"Lehrbuch der Allgemeinen Chemie","author":"Ostwald","year":"1896"},{"key":"10.1016\/j.ejpb.2017.12.016_b0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Federation Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005964","article-title":"Drug carrier systems for solubility enhancement of BCS Class II drugs: a critical review","volume":"30","author":"Kumar","year":"2013","journal-title":"Crit. Rev.\u2122 Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2017.12.016_b0160","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1021\/cg801039j","article-title":"Solubility advantage of pharmaceutical cocrystals","volume":"9","author":"Good","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2017.12.016_b0165","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1021\/cg1002176","article-title":"Effect of micellar solubilization on cocrystal solubility and stability","volume":"10","author":"Huang","year":"2010","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2017.12.016_b0170","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1021\/mp300189b","article-title":"pH-Dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media","volume":"9","author":"Alhalaweh","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0175","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/mp400176y","article-title":"Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability","volume":"10","author":"Childs","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0180","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.lfs.2003.06.017","article-title":"Anxiolytic-like effect of succinic acid in mice","volume":"73","author":"Chen","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2017.12.016_b0185","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/cg200704s","article-title":"Fast dissolving curcumin cocrystals","volume":"11","author":"Sanphui","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2017.12.016_b0190","series-title":"A Guide to IUPAC Nomenclature of Organic Compounds","author":"Panico","year":"1992"},{"key":"10.1016\/j.ejpb.2017.12.016_b0195","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3923\/ajft.2007.679.683","article-title":"Phenols and polyphenols from Argania spinosa","volume":"2","author":"Charrouf","year":"2007","journal-title":"Am. J. Food Technol."},{"key":"10.1016\/j.ejpb.2017.12.016_b0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","article-title":"Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa","volume":"35","author":"Boer","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejpb.2017.12.016_b0205","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/mp8000793","article-title":"Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview","volume":"5","author":"Friesen","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.12.016_b0210","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s11095-012-0695-7","article-title":"Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications","volume":"29","author":"Qian","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.12.016_b0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.xphs.2016.07.018","article-title":"Mitigating cocrystal physical stability liabilities in preclinical formulations","volume":"106","author":"Bhardwaj","year":"2017","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117308974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117308974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T04:00:26Z","timestamp":1603598426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117308974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":42,"alternative-id":["S0939641117308974"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.12.016","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral bioavailability enhancement of \u03b2-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}